Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece
- PMID: 22818870
- DOI: 10.1016/j.clinthera.2012.07.002
Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece
Abstract
Background: Varenicline was designed to relieve symptoms of nicotine withdrawal, including cigarette craving, and to block the reinforcing effects of continued nicotine use. The cost-effectiveness of varenicline in some countries has not been studied.
Objective: The aim of this study was to compare the cost-effectiveness of varenicline to that of bupropion, nicotine-replacement therapy (NRT), and unaided cessation in the Greek health care setting. The analysis takes into account a societal security (third-party payer) perspective.
Methods: To perform the analyses of the benefits of smoking cessation in terms of smoking-related morbidity, mortality, and associated medical costs, a Markov model was used that simulated the progress of a hypothetical cohort of current smokers making a single attempt to quit smoking at the beginning of the timeframe of the analysis. The robustness of the results was assessed using a series of 1-way sensitivity analyses.
Results: Varenicline was associated with the potential prevention of 14.1, 14.2, and 35.1 additional cases of the 4 smoking-related diseases incorporated into the model, per 1000 smokers willing to quit, versus bupropion, NRT, and unaided cessation, respectively. Potentially avoided smoking-related deaths with varenicline were estimated at 3.24, 3.26, and 7.5 per 1000 quitters versus the 3 comparators. Varenicline led to a potential gain of 33.78, 33.91, and 83.97 QALYs per 1000 persons willing to make a quit attempt versus the 3 comparators. Varenicline was associated with cost-savings against both active comparators for the lifetime horizon. Overall, the cost per additional quitter with varenicline, considering only the costs of the smoking-cessation strategy, was €2659 (€1015) for a lifetime horizon compared with bupropion (NRT); however, when all direct costs were incorporated into the analysis, varenicline was cost-saving.
Conclusion: The findings from the present study suggest that, compared with the widely used treatment options bupropion and NRT, as well as unaided cessation, varenicline may enhance smoking-cessation treatment outcomes while substantially reducing the overall costs of smoking to the health care system.
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
Similar articles
-
Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.Hosp Pract (1995). 2012 Feb;40(1):24-34. doi: 10.3810/hp.2012.02.945. Hosp Pract (1995). 2012. PMID: 22406880
-
Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.Curr Med Res Opin. 2010 Mar;26(3):549-60. doi: 10.1185/03007990903542666. Curr Med Res Opin. 2010. PMID: 20050814
-
Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.Hosp Pract (1995). 2012 Feb;40(1):35-43. doi: 10.3810/hp.2012.02.946. Hosp Pract (1995). 2012. PMID: 22406881
-
Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Pharmacoeconomics. 2010. PMID: 20108995 Review.
-
Varenicline in the management of smoking cessation: a single technology appraisal.Health Technol Assess. 2009 Sep;13 Suppl 2:9-13. doi: 10.3310/hta13suppl2/02. Health Technol Assess. 2009. PMID: 19804684 Review.
Cited by
-
Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.Health Technol Assess. 2023 Mar;27(4):1-277. doi: 10.3310/KLTG1447. Health Technol Assess. 2023. PMID: 37022933 Free PMC article.
-
The Cost-Effectiveness of Nicotine Replacement Therapy Sampling in Primary Care: a Markov Cohort Simulation Model.J Gen Intern Med. 2022 Nov;37(14):3684-3691. doi: 10.1007/s11606-021-07335-x. Epub 2022 Jan 28. J Gen Intern Med. 2022. PMID: 35091913 Free PMC article.
-
Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.Value Health. 2021 Jun;24(6):780-788. doi: 10.1016/j.jval.2020.12.012. Epub 2021 Mar 11. Value Health. 2021. PMID: 34119075 Free PMC article.
-
Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial.Addiction. 2020 Mar;115(3):507-517. doi: 10.1111/add.14829. Epub 2019 Dec 4. Addiction. 2020. PMID: 31597207 Free PMC article. Clinical Trial.
-
An examination of user costs in relation to smokers using a cessation service based in the UK.BMC Health Serv Res. 2018 Mar 15;18(1):182. doi: 10.1186/s12913-018-2985-1. BMC Health Serv Res. 2018. PMID: 29544477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical